Macrogenics Q2 EPS $0.92 Beats $(0.52) Estimate, Sales $13.14M Miss $29.74M Estimate
Portfolio Pulse from vinayak@benzinga.com
Macrogenics reported Q2 earnings of $0.92 per share, beating the analyst consensus estimate of $(0.52) by 276.92%. However, the company's quarterly sales of $13.14 million missed the analyst consensus estimate of $29.74 million by 55.83%. This represents a 49.49% decrease over sales of $26.01 million the same period last year.
August 09, 2023 | 8:08 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Macrogenics' Q2 earnings beat estimates but sales missed, indicating mixed financial performance.
Macrogenics' Q2 earnings beat the analyst consensus estimate by a significant margin, which is a positive signal for the company's profitability. However, the company's sales missed the estimate by a large margin, indicating potential issues with revenue generation. This mixed financial performance could lead to uncertainty in the market, potentially impacting the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100